Kathy D. Miller, MD - Strategies to Improve PFS in Advanced Breast Cancer: Examining the Role of Antiangiogenic Agents in the Context of Other Therapies

Summary: In this activity, experts present current data on antiangiogenic therapies in metastatic breast cancer (MBC). Clinical relevance of the endpoints used with cytostatic targeted agents and cytotoxic chemotherapeutics in MBC is evaluated. Recent efficacy and safety data from studies evaluating antiangiogenic therapies in advanced disease are summarized and interpreted, and practical recommendations for optimal integration of angiogenesis inhibitors into the treatment of MBC are provided.